Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

ClinicalTrials.gov ID: NCT00891293

Public ClinicalTrials.gov record NCT00891293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00891293
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
93 participants

Conditions and interventions

Interventions

  • Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008
Last update posted
Jan 24, 2011

2006 – 2008

United States locations

U.S. sites
32
U.S. states
19
U.S. cities
30
Facility City State ZIP Site status
GSK Investigational Site Spring Valley California 91978
GSK Investigational Site Washington D.C. District of Columbia 20037
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Hollywood Florida 33023
GSK Investigational Site Jacksonville Florida 32216
GSK Investigational Site Jacksonville Florida 32259
GSK Investigational Site Longwood Florida 32779
GSK Investigational Site Pinellas Park Florida 33781
GSK Investigational Site Duhwoody Georgia 30338
GSK Investigational Site Chicago Illinois 60610
GSK Investigational Site Bloomington Indiana 47403
GSK Investigational Site Louisville Kentucky 40213
GSK Investigational Site Auburn Maine 04210
GSK Investigational Site Scarborough Maine 04074
GSK Investigational Site Baltimore Maryland 21209
GSK Investigational Site Wentzville Minnesota 62285
GSK Investigational Site Kansas City Missouri 64111
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Statesville North Carolina 28677
GSK Investigational Site Winston-Salem North Carolina 27106
GSK Investigational Site Cincinnati Ohio 45212
GSK Investigational Site Cincinnati Ohio 45219
GSK Investigational Site Oklahoma City Oklahoma 73103
GSK Investigational Site Cumberland Rhode Island 02864
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Norfolk Virginia 23502
GSK Investigational Site Richmond Virginia 23294
GSK Investigational Site Winchester Virginia 22601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00891293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 24, 2011 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00891293 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →